Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769527 | 0.96 | ALDH1A1 (0.46) | DRD3KDM4EALDH1A1POLBGAA | |
| SCHEMBL21769231 | 0.91 | DRD3 (0.54) | DRD3KDM4EALDH1A1POLBKCNA5 | |
| SCHEMBL21769465 | 0.90 | KDM4E (0.49) | DRD3KDM4EALDH1A1POLB | |
| SCHEMBL21769466 | 0.88 | KDM4E (0.50) | DRD3KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL21769525 | 0.86 | USP2 (0.50) | KDM4EALDH1A1POLB | |
| SCHEMBL21769401 | 0.86 | ALDH1A1 (0.53) | DRD3KDM4EALDH1A1POLBGAA | |
| SCHEMBL21769246 | 0.86 | FNTA (0.43) | KDM4EALDH1A1 | |
| SCHEMBL21769409 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL21769463 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1 | |
| SCHEMBL21769529 | 0.83 | NPSR1 (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | DRD3 3732/4885KDM4E 3638/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.